Capsulin OAD is under clinical development by Diabetology (Products) and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Capsulin OAD’s likelihood of approval (LoA) and phase transition for Type 2 Diabetes took place on 05 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Capsulin OAD Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Capsulin OAD overview

Capsulin OAD (oral anti-diabetic) is under development for the treatment of type 2 diabetes. It is an oral encapsulated formulation of recombinant human insulin which acts by targeting insulin receptor. It is developed based on Axcess drug delivery technology.

Diabetology (Products) overview

Diabetology (Products) (Diabetology), a subsidiary of Proxima Concepts Ltd, is a biopharmaceutical company that develops oral drugs for the treatment of diabetes. The company provides oral delivery system to administer bioactives and compounds to transform the treatment outcomes for patients with diabetes. Its pipeline products include capsulin OAD, capsulin IR, oral GLP-1 analogue and combulin. Diabetology offers axcess, a system that increases the absorption of peptides, proteins and other macromolecules. Its capsulin OAD is an oral anti-diabetic used in the treatment of type 2 diabetes mellitus and oral GLP-1 analogue reduces glucose output from the liver and improves insulin sensitivity and the function of beta-cells. The company has operations in the UK and Australia. Diabetology is headquartered in Jersey, the UK.

Quick View Capsulin OAD LOA Data

Report Segments
  • Innovator
Drug Name
  • Capsulin OAD
Administration Pathway
  • Oral
Therapeutic Areas
  • Metabolic Disorders
Key Developers
  • Sponsor Company: Diabetology (Products)
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.